If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Law MY, Halliwell B (1986). "Purification and properties of glutathione synthetase from (Spinacia oleracea) leaves". Plant Sci. 43 (3): 185–191. doi:10.1016/0168-9452(86)90016-6. Macnicol PK (1987). "Homoglutathione and glutathione synthetases of legume seedlings - partial-purification and substrate-specificity". Plant Sci. 53 (3): 229–235. Bibcode:1987PlnSc..53..229M. doi:10.1016/0168-9452(87)90159-2.
Pudafensine (INNTooltip International Nonproprietary Name; developmental code name IP2015 among others) is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) which is under development for the treatment of erectile dysfunction, neuropathic pain, trigeminal neuralgia, vulvodynia, female sexual dysfunction, pain, and substance-related disorders. It is taken orally. The drug has been found to induce penile erection in male rodents and to increase genital blood flow and paracopulatory behaviors in female rodents. A close analogue of pudafensine is the earlier SNDRI NS18283. Pudafensine is under development by Initiator Pharma. As of July 2025, it is in phase 2 clinical trials for erectile dysfunction, phase 1 trials for neuropathic pain, trigeminal neuralgia, and vulvodynia, and the preclinical research stage of development for female sexual dysfunction, pain, and substance-related disorders.
=== Assessment === Although CoQ10 may be measured in blood plasma, these measurements reflect dietary intake rather than tissue status. Currently, most clinical centers measure CoQ10 levels in cultured skin fibroblasts, muscle biopsies, and blood mononuclear cells. Culture fibroblasts can be used also to evaluate the rate of endogenous CoQ10 biosynthesis, by measuring the uptake of 14C-labeled p-hydroxybenzoate. CoQ10 is studied as an adjunctive therapy to reduce inflammation in periodontitis.
showed that small molecule inhibitors of Prp8 intein splicing were selective and effective at slowing the growth of C. neoformans and C. gattii, providing exciting evidence for the antimicrobial potential of intein splicing inhibitors.
Sources: en.wikipedia.org
=== Li–Lu === Andreas Libavius (1555–1616), German doctor and alchemist who discovered how prepare hydrochloric acid, ammonium sulfate, etc. Carl Theodore Liebermann (1842–1914), German chemist, known for synthesis of alizarin Willard Libby (1908–1980), American chemist known for development of radiocarbon dating, 1960 Nobel Prize in Chemistry Justus von Liebig (1803–1873), German inventor and pioneer in agricultural and biological chemistry Karl Paul Link (1901–1978), American biochemist, discovered the anticoagulant warfarin John Wilfrid Linnett (1913–1975), British chemist at the Universities of Oxford and Cambridge, known for contributions to theoretical chemistry William Lipscomb (1919–2011), American chemist known for work in nuclear magnetic resonance, theoretical chemistry, boron chemistry, and biochemistry; 1976 Nobel Prize in Chemistry Joseph Lister, 1st Baron Lister (1827–1912), English surgeon known for recognising that putrefaction in wounds is caused by germs Arthur H. Livermore (1915–2009), American science educator and chemist who contributed to the synthesis of penicillin Mikhail Lomonosov (1711–1765), Russian scientist, anticipated the kinetic-molecular theory by 100 years H.
In the colon, for example, the muscular layer is much thicker because the faeces are large and heavy and require more force to push along. The outer longitudinal layer of the colon thins out into 3 discontinuous longitudinal bands, known as taeniae coli (bands of the colon). This is one of the 3 features helping to distinguish between the large and small intestine. Occasionally in the large intestine (2-3 times a day), there will be mass contraction of certain segments, moving a lot of faeces along. This is generally when one gets the urge to defecate. The pylorus of the stomach has a thickened portion of the inner circular layer: the pyloric sphincter. Alone among the GI tract, the stomach has a third layer of muscular layer. This is the inner oblique layer and helps churn the chyme in the stomach.
=== Contamination === A 2011 survey of 33 supplements commercially available in Italy found that over 50% of them exceeded the European Food Safety Authority recommendations in at least one contaminant. The most prevalent of these contaminants was creatinine, a breakdown product of creatine also produced by the body. Creatinine was present in higher concentrations than the European Food Safety Authority recommendations in 44% of the samples. About 15% of the samples had detectable levels of dihydro-1,3,5-triazine or a high dicyandiamide concentration. Heavy metals contamination was not found to be a concern, with only minor levels of mercury being detectable. Two studies reviewed in 2007 found no impurities.'
Sources: en.wikipedia.org
=== Men's physique === Due to those who found open-bodybuilding to be "too big" or "ugly" and unhealthy, a new category was started in 2013. The first Men's Physique Olympia winner was Mark Wingson, who was followed by Jeremy Buendia for four consecutive years. Like open-bodybuilding, the federations in which bodybuilders can compete are natural divisions as well as normal ones. The main difference between the two is that men's physique competitors pose in board shorts rather than a traditional posing suit and open-bodybuilders are much larger and are more muscular than the men's physique competitors. Open-bodybuilders have an extensive routine for posing while the Physique category is primarily judged by the front and back poses. Many of the men's physique competitors are not above 200 lbs and have a bit of a more attainable and aesthetic physique in comparison to open-bodybuilders. Although this category started off slowly, it has grown tremendously, and currently men's physique seems to be a more popular class than open-bodybuilding.
Little Feat co-founder and pianist Bill Payne, known for his contributions to many of the band's early studio albums, was selected to temporarily fill in for Allison in his absence. The Doobies and Michael McDonald were the featured musical guests on The Tonight Show Starring Jimmy Fallon in 2015, where they performed a medley of "Long Train Runnin'" and "Takin' It to the Streets". The band also performed a web-exclusive performance of "What a Fool Believes" that was made available on The Tonight Show's website. In October 2015 Payne officially took over Guy Allison's duties as the Doobies' keyboardist, whilst remaining an active member of Little Feat. The next month, the Doobie Brothers together with Journey launched a tour featuring Dave Mason. The pairing with Journey continued in 2016, beginning at the Irvine Meadows Amphitheatre and concluding when the Doobies and Journey joined the Steve Miller Band and Santana at AT&T Park. They also appeared at Warren Haynes Christmas Jam in 2015, however Johnston did not appear due to knee surgery. In 2016 the Doobie Brothers signed under new management with Irving Azoff. Tony Pia left in the summer, leaving Ed Toth as the band's sole drummer. In 2017 the Doobie Brothers toured with Chicago once again, beginning at the Concord Pavilion and wrapping up in Virginia Beach. They also appeared with the Eagles and Steely Dan at the Classic concerts for two weekends in 2017. These concerts took place at Dodger Stadium (Classic West) and at Citi Field (Classic East).
In 1947, David Lester and Leon Greenberg found strong evidence that paracetamol was a major metabolite of acetanilide in human blood, and in a subsequent study, they reported that large doses of paracetamol given to albino rats did not cause methemoglobinemia. In 1948, Bernard Brodie, Julius Axelrod and Frederick Flinn confirmed that paracetamol was the major metabolite of acetanilide in humans, and established that it was just as efficacious an analgesic as its precursor. They also suggested that methemoglobinemia is produced in humans mainly by another metabolite, phenylhydroxylamine. A follow-up paper by Brodie and Axelrod in 1949 established that phenacetin was also metabolized to paracetamol. This led to a "rediscovery" of paracetamol. Paracetamol was first marketed in the United States in 1950 under the name Trigesic, a combination of paracetamol, aspirin, and caffeine. Reports in 1951 of three users stricken with the blood disease agranulocytosis led to its removal from the marketplace, and it took several years until it became clear that the disease was unconnected. The following year, 1952, paracetamol returned to the U.S. market as a prescription drug. In the United Kingdom, marketing of paracetamol began in 1956 by Sterling-Winthrop Co. as Panadol, available only by prescription, and promoted as preferable to aspirin since it was safe for children and people with ulcers.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.